AIT 2023: Current innovation and future outlook

Magdalena Zemelka-Wiacek; Marek Jutel

doi:10.5414/ALX02379E

AIT 2023: Current innovation and future outlook

Allergol Select. 2023 Dec 12:7:219-228. doi: 10.5414/ALX02379E. eCollection 2023.

Authors

Magdalena Zemelka-Wiacek¹, Marek Jutel^{1

2}

Affiliations

¹ Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, and.
² ALL-MED Medical Research Institute, Wroclaw, Poland.

Abstract

Although used for over 100 years, allergen immunotherapy (AIT) is still an indispensable tool in modern allergy managemen20t due to its potential to cure allergic diseases. Its current rapid development through the application of personalized and precision medicine approaches is strongly supported by advances in mHealth, component-resolved diagnosis (CRD)-based diagnostics, validation of novel biomarkers, advanced data management, and development of novel preparations. This review summarizes the key advances in the field and shows the perspectives for further development of next-generation AIT treatments.

Keywords: allergen immunotherapy (AIT); biologicals; biomarkers; component-resolved diagnosis (CRD); randomized controlled trial (RCT); real-world evidence (RWE).

Publication types

Review